share_log

中國抗體-B:自願公告 國家藥監局藥品審評中心受理舒西利單抗(SUCIRASLIMAB, SM03) 用於治療阿爾茨海默病的新藥研究申請

SINOMAB BIO-B: VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM03 (SUCIRASLIMAB) FOR THE TREATMENT OF ALZHEIMER''S DISEASE ACCEPTED BY NMPA CDE

香港交易所 ·  Nov 15, 2023 06:51
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more